Latest & greatest articles for paroxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on paroxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on paroxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for paroxetine

1. Paroxetine

Paroxetine Top results for paroxetine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for paroxetine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years?

Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years? Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60 years? | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60 years? Article Text Further commentaries Electronic pages Pharmacological interventions Are sertraline, paroxetine

Evidence-Based Mental Health2016

3. Randomised controlled trial: Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety

Randomised controlled trial: Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety Article Text Therapeutics/Prevention Randomised controlled

Evidence-Based Medicine (Requires free registration)2016

4. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.

Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. OBJECTIVES: To reanalyse SmithKline Beecham's Study 329 (published by Keller and colleagues in 2001), the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The reanalysis under the restoring invisible and abandoned trials (RIAT) initiative was done to see (...) . INTERVENTIONS: Participants were randomised to eight weeks double blind treatment with paroxetine (20-40 mg), imipramine (200-300 mg), or placebo. MAIN OUTCOME MEASURES: The prespecified primary efficacy variables were change from baseline to the end of the eight week acute treatment phase in total Hamilton depression scale (HAM-D) score and the proportion of responders (HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) at acute endpoint. Prespecified secondary outcomes were changes from baseline

BMJ2015

5. Paroxetine

Paroxetine USE OF PAROXETINE IN PREGNANCY 0344 892 0909 USE OF PAROXETINE IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression, obsessive-compulsive disorder, post-traumatic stress disorder, anxiety disorders (generalised or social) and panic disorder with or without agoraphobia. Data on the risk of congenital malformations following paroxetine use in early pregnancy are conflicting; the majority of individual studies have demonstrated no statistically significant increase in the overall risk of any malformation or of cardiac malformations specifically. However, some, but not all, meta

UK Teratology Information Service2014

6. Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder

Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Gonzalez Rodriguez A, Gasto Ferrer C, Navarro Odriozola V CRD summary The authors concluded that mirtazapine was effective earlier, but at six to eight weeks, paroxetine was equally (...) effective for the treatment of major depressive disorder. There were some methodological limitations, and no validity assessment, leaving the reliability of the conclusions uncertain. Authors' objectives To compare the efficacy and tolerability of paroxetine with those of mirtazapine for the treatment of major depressive disorder. Searching PubMed and PsycINFO were searched for articles from 1980 to June 2011; search terms were reported. It appears that published systematic reviews were checked

DARE.2013

7. Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Article Text Aetiology Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Evidence-Based Mental Health2012

8. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial 21314870 2011 02 14 2011 12 22 2014 11 20 1742-1241 65 3 2011 Mar International journal of clinical practice Int. J. Clin. Pract. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. 323-9 10.1111/j.1742-1241.2010.02624.x (...) Prominent anxiety symptoms are related to poor clinical course and outcome in major depressive disorder (MDD). The aim of this randomised, open-label, controlled study is to compare the efficacy and tolerability of mirtazapine in the form of orally disintegrating tablets against paroxetine in treating MDD patients with anxiety symptoms. A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine

EvidenceUpdates2011

9. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine

Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine Gentile S, Bellantuono C CRD summary This review concluded that the data were too inconsistent (...) to confirm or exclude the risk of major foetal malformations after exposure to paroxetine during early pregnancy. The review had major flaws in terms of an unreported review process and absence of study quality assessment. The extent to which the conclusion is a reliable assessment of the evidence base is unclear. Authors' objectives To assess the effect of prenatally administered paroxetine on the prevalence of major foetal malformations. Searching MEDLINE, TOXNET, EMBASE, and the Cochrane Library were

DARE.2009

10. Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder

Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Article Text Therapeutics Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2008

11. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized (...) trials Barbui C, Furukawa T A, Cipriani A CRD summary This review evaluated the effectiveness and acceptability of paroxetine in major depression, concluding paroxetine was not superior to placebo in terms of the proportion of study participants discontinuing treatment for any reason. Paoxetine had a modest effect in terms of depression measures. The conclusions appeared broadly appropriate, although they possibly overemphasised the less meaningful efficacy outcome of treatment withdrawal. Authors

DARE.2008

12. Does paroxetine cause cardiac malformations?

Does paroxetine cause cardiac malformations? Does paroxetine cause cardiac malformations? Does paroxetine cause cardiac malformations? O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G CRD summary This generally well-conducted review of non-randomised studies concluded that first trimester exposure to paroxetine did not appear to be associated with increased rates of cardiac malformations. This conclusion reflects the results of this review of reasonable quality studies that included (...) a large number of women and is likely to be reliable. Authors' objectives To determine whether first trimester exposure to paroxetine is associated with an increased rate of cardiac defects. Searching MEDLINE, EMBASE, REPROTOX, Scopus and Biological Abstracts were searched from January 1985 to November 2007. No language restrictions were reported. Search terms were reported. References of retrieved articles, proceedings of professional societies in relevant fields and Internet sites were searched

DARE.2008

13. Review: paroxetine and placebo do not differ for treatment discontinuation in major depression

Review: paroxetine and placebo do not differ for treatment discontinuation in major depression Review: paroxetine and placebo do not differ for treatment discontinuation in major depression | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: paroxetine and placebo do not differ for treatment discontinuation in major depression Article Text Therapeutics Review: paroxetine and placebo do not differ for treatment discontinuation in major depression Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2008

14. Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people

Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people Article Text Therapeutics Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people Statistics from

Evidence-Based Medicine (Requires free registration)2007

15. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis

Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis Katzman M A, Tricco A C, McIntosh D, Filteau M J, Bleau P, Chokka P R, Kjernisted K D, Mok H, Pham B CRD summary This review concluded that there were no consistent and valid (...) differences to suggest that multiple modes of action improved clinical outcomes between paroxetine and other antidepressants for depressive disorders. This was a generally well-conducted review. The authors' conclusions appear to be reliable. Authors' objectives To examine the efficacy of paroxetine versus placebo and other antidepressants in the treatment of depressive disorders. Searching MEDLINE, EMBASE, CINAHL, all Evidence-Based Medicine Reviews, HealthSTAR, BIOSIS Previews and PsycINFO were searched

DARE.2007

16. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors

Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G CRD summary This review investigated whether first-trimester exposure to paroxetine is associated (...) with an increased risk of congenital malformations. The authors concluded that first trimester exposure to paroxetine appears to be associated with a significant increase in the risk of cardiac malformation. However, the reliability of these conclusions is unclear as insufficient details of the included studies were provided. Authors' objectives To investigate whether first-trimester exposure to paroxetine is associated with an increased risk of congenital malformations. Searching MEDLINE, EMBASE, REPROTOX

DARE.2007

17. St John’s wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated

St John’s wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated St John’s wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here St John’s wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated Article Text Therapeutics St John’s wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated Free Professor Edzard

Evidence-Based Mental Health2006

18. Paroxetine improves social anxiety disorder in children and adolescents

Paroxetine improves social anxiety disorder in children and adolescents Paroxetine improves social anxiety disorder in children and adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paroxetine improves social anxiety disorder in children and adolescents Article Text Therapeutics Paroxetine improves social anxiety disorder in children and adolescents Free Katharina Manassis , MD, FRCP(C) Statistics from Altmetric.com No Altmetric data available for this article. Wagner KD, Berard R, Stein MB, et al . A multicenter, randomized, double-blind

Evidence-Based Mental Health2006

19. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom

Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Jorgensen T R, Stein D J, Despiegel N, Drost P B, Hemels M E, Baldwin D S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared escitalopram (10 to 20 mg/day) and paroxetine (20 to 50 mg/day) as the first-line treatment for generalised anxiety disorder (GAD). Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2006

20. Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people

Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major depression in older people Article Text Treatment Maintenance treatment with paroxetine, but not psychotherapy, prevented recurrent major

Evidence-Based Nursing (Requires free registration)2006